Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 19

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 As of December 31, 2024, there are no amounts due or
outstanding under the convertible note purchase agreement with Oncotelic

On July 1, 2024, we entered into a Master Services
Agreement with Oncotelic whereby we perform advisory and related services in connection with studies and projects. For the three and six
months ended June 30, 2025, we earned $0 and $14,000, respectively, for advisory and related services which is recorded in other income
in the accompanying unaudited condensed consolidated statement of operations.

     15 

    12.
    Subsequent Events

We have evaluated subsequent events after the consolidated
balance sheet date and through the filing date of this Quarterly Report, and based on our evaluation, management has determined that no
other subsequent events have occurred that would require recognition in the accompanying unaudited condensed consolidated financial statements
or disclosure in the notes thereto other than as disclosed in the accompanying notes.

 16 

    Item 2.
    Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the financial
condition and results of our operations should be read together with the financial statements and related notes of Mosaic ImmunoEngineering,
Inc. included in Part I Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and the
related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024.

Unless the context otherwise requires, references
to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us”
in this Quarterly Report refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements
that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly
Report, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations
for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such
as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue”
or the negative of these terms or other comparable terminology.

In addition to historical information, this